Microbot Medical Inc

Microbot Medical reports revenue growth of over 100% in the second fiscal quarter compared with the prior quarter and filed Form 10‑Q with the SEC. Drivers were follow‑on orders, expanded usage by existing customers and new customer wins after the full market launch of the endovascular robotic system LIBERTY in mid‑April. The company expanded its sales territories from four to eight states, increased the number of hospital sites, plans to reach twelve territories by year‑end and signed contracts to supply government health systems as well as to establish a second production site. Israel also granted market approval for the LIBERTY system as the second jurisdiction after the USA. » More on de.investing.com

Microbot Medical amended the employment agreement of CFO Rachel Vaknin and will increase her annual base salary to 864,000 NIS effective August 1, 2026 (about $288,000 at a 3:1 exchange rate, according to the company). The change is set out in Amendment No. 4 to the contract and disclosed in an 8-K filed with the SEC. The adjustment comes despite ongoing profitability problems (last 12 months: gross profit margin 1.9%); the company will publish quarterly results on August 18. » More on de.investing.com

Microbot Medical has signed a letter of intent with Sanmina under which Sanmina will take over manufacturing of the FDA-approved, remotely operated disposable system LIBERTY. The partnership is intended to serve as a second manufacturing site to increase production capacity, reduce costs and improve operational efficiency while Microbot advances its market expansion. The company has more cash than debt, plans to obtain CE approval and expand distribution in the western US, and is preparing to scale up production. » More on de.investing.com